AI Engines For more Details: Perplexity Kagi Labs You
Hypercholesterolemia: Pravastatin is indicated for the treatment of primary hypercholesterolemia (elevated levels of cholesterol in the blood) and mixed dyslipidemia (elevated levels of both cholesterol and triglycerides). It works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol synthesis in the liver. By reducing the production of cholesterol, pravastatin helps lower LDL cholesterol (often referred to as "bad" cholesterol) and total cholesterol levels in the blood.
Prevention of Cardiovascular Events: Pravastatin is used as an adjunct to dietary therapy to reduce the risk of cardiovascular events in individuals with established coronary heart disease, including those who have had a heart attack or unstable angina, and those with a history of coronary revascularization procedures such as angioplasty or coronary artery bypass grafting (CABG). By lowering cholesterol levels, pravastatin helps prevent the progression of atherosclerosis (build-up of plaque in the arteries) and reduces the risk of cardiovascular events such as heart attack, stroke, and transient ischemic attack (TIA).
Prevention of Stroke: Pravastatin may be used to reduce the risk of stroke in individuals with a history of stroke or transient ischemic attack (TIA). By lowering cholesterol levels and stabilizing atherosclerotic plaques in the arteries supplying the brain, pravastatin helps reduce the risk of recurrent stroke.
Peripheral Arterial Disease (PAD): Pravastatin is sometimes prescribed to individuals with peripheral arterial disease, a condition characterized by narrowing of the arteries in the legs and feet due to atherosclerosis. By improving blood flow to the lower extremities and reducing the risk of blood clots, pravastatin helps alleviate symptoms such as leg pain and cramping during physical activity.
Diabetes: Pravastatin may be beneficial for individuals with diabetes, particularly those with dyslipidemia and other cardiovascular risk factors. By improving lipid profiles and reducing the risk of cardiovascular events, pravastatin contributes to the management of cardiovascular risk in diabetic patients.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.3 | 0.3 | |
Allergic Rhinitis (Hay Fever) | 0.6 | 0.2 | 2 |
Allergies | 0.8 | 0.8 | |
Allergy to milk products | 0.2 | 0.6 | -2 |
Alzheimer's disease | 0.6 | 0.9 | -0.5 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.2 | 2 |
Ankylosing spondylitis | 0.8 | 0.8 | |
Anorexia Nervosa | 0.3 | -0.3 | |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.2 | 0.2 | |
Atherosclerosis | 0.2 | 0.2 | |
Atrial fibrillation | 0.3 | 0.6 | -1 |
Autism | 0.6 | 0.8 | -0.33 |
Autoimmune Disease | 0.6 | 0.6 | |
benign prostatic hyperplasia | 0.6 | 0.6 | |
Biofilm | 0.2 | 0.2 | |
Bipolar Disorder | 0.6 | 0.6 | |
Breast Cancer | 0.2 | 0.2 | |
Carcinoma | 0.6 | 0.6 | |
Celiac Disease | 0.2 | 0.2 | |
Chronic Fatigue Syndrome | 0.2 | 0 | 0 |
Chronic Kidney Disease | 0.6 | 0 | 0 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.2 | |
Chronic Urticaria (Hives) | 0.8 | 0.8 | |
Coagulation / Micro clot triggering bacteria | 0.8 | 0.8 | |
Colorectal Cancer | 0.8 | 0.5 | 0.6 |
Constipation | 0.6 | 0.6 | |
Coronary artery disease | 1.1 | 0 | 0 |
COVID-19 | 0.8 | 0.3 | 1.67 |
Crohn's Disease | 0.8 | 0 | 0 |
cystic fibrosis | 0.8 | 0.8 | |
d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
deep vein thrombosis | 0.8 | 0.8 | |
Depression | 0.8 | 0.9 | -0.13 |
Eczema | 0.6 | 0.6 | |
Endometriosis | 0.8 | 0.2 | 3 |
Epilepsy | 0.8 | 0.8 | |
erectile dysfunction | 0.6 | 0.6 | |
Functional constipation / chronic idiopathic constipation | 0.8 | 0.8 | |
gallstone disease (gsd) | 0.8 | 0.8 | |
Generalized anxiety disorder | 0.8 | 0.8 | |
Heart Failure | 0.8 | 0 | 0 |
High Histamine/low DAO | 0.2 | 0.2 | |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
hyperglycemia | 0.8 | 0.8 | |
hypertension (High Blood Pressure | 0.6 | 0.6 | |
Hypoxia | 0.8 | 0.8 | |
Inflammatory Bowel Disease | 0.8 | 0.5 | 0.6 |
Insomnia | 0.3 | -0.3 | |
Intelligence | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 0.8 | 0.8 | |
ischemic stroke | 0.2 | 0.9 | -3.5 |
Liver Cirrhosis | 1.1 | 0.2 | 4.5 |
Long COVID | 0.9 | 0.3 | 2 |
Lung Cancer | 0.6 | 0.6 | |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.6 | 0.6 | |
Metabolic Syndrome | 0.8 | 0.8 | |
Mood Disorders | 0.6 | 0.9 | -0.5 |
Multiple Sclerosis | 0.6 | 0 | 0 |
myasthenia gravis | 0.6 | 0.6 | |
Neuropathy (all types) | 0.6 | -0.6 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 0 | 0 |
Obesity | 0.8 | 0.8 | |
obsessive-compulsive disorder | 0.8 | 0.3 | 1.67 |
Osteoarthritis | 0.6 | 0.6 | |
Osteoporosis | 0.6 | 0.6 | |
Parkinson's Disease | 0.8 | 1.5 | -0.88 |
Polycystic ovary syndrome | 0.6 | 0.6 | |
Psoriasis | 0.2 | 0 | 0 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0 | 0 |
scoliosis | 0.2 | 0.2 | |
Sjögren syndrome | 0.6 | 0.3 | 1 |
Slow gastric motility / Gastroparesis | 0.2 | 0.2 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
Stress / posttraumatic stress disorder | 0.2 | 0.2 | |
Systemic Lupus Erythematosus | 0.6 | 0.6 | 0 |
Type 1 Diabetes | 0.6 | 0.6 | |
Type 2 Diabetes | 1.1 | 0.2 | 4.5 |
Ulcerative colitis | 0.8 | 0.8 | |
Unhealthy Ageing | 0 | 0 |